DWTX Dogwood Therapeutics, Inc.
USHealthcareAs of 2026-07-10 12:49
Why DWTX matters now
Dogwood Therapeutics, Inc. (DWTX) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.40 with -0.71% on the session and $2.7M in market capitalization; recent performance reads 1-month -16.22% and YTD -62.74%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-5.0M, and EPS of $-0.15. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -524.0%.
The latest indexable market news headline is "Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Keefer David R filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.64
P/S
0.00
EV/EBITDA
0.36
DCF Value
$0.69
FCF Yield
-524.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-35.9%
ROA
-29.7%
ROIC
-30.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-5.0M | $-0.15 |
| Q4 2025 | $0.00 | $-3.8M | $-0.26 |
| FY 2025 | $0.00 | $-34.3M | $-4.32 |
| Q3 2025 | $0.00 | $-15.7M | $-8.20 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.71
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.